Annotation Detail

Information
Associated Genes
ABL1
Associated Variants
ABL1 FOXP1-ABL1 Fusion
Associated Disease
Pediatric B-lymphoblastic Leukemia
Source Database
CIViC Evidence
Description
A 16-year-old Caucasian boy was diagnosed with B-ALL. Karyotype showed an abnormal clone characterized by the t(3;9)(p13;q34.1). This translocation results in an abnormal fusion between the FOXP1 gene in 3p13 and the ABL1 in 9q34.1. The FOXP1-ABL1 fusion is known to be associated with Ph-like B-ALL subtype of B-ALL. The patient was treated with Berlin-Frankfurt-Münster (BFM) high-risk 4-drug induction chemotherapy with prednisone, daunorubicin, vincristine, and pegasparaginase and had 0.013% MRD at the end of indusciton. Tyrosine kinase inhibitor dasatinib was added to the consolidationchemotherapy with cyclophosphamide, cytarabine, peg-asparaginase, mercaptopurine, and vincristine. End-of-consolidation bone marrow tested negative for MRD. The patient was continued on standard high-risk BFM therapy, plus dasatinib.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7292
Gene URL
https://civic.genome.wustl.edu/links/genes/4
Variant URL
https://civic.genome.wustl.edu/links/variants/2698
Rating
1
Evidence Type
Predictive
Disease
Pediatric B-lymphoblastic Leukemia
Evidence Direction
Supports
Drug
Dasatinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
30938769
Drugs
Drug NameSensitivitySupported
DasatinibSensitivitytrue